Cita APA (7a ed.)
Xavier, M. S., Trajman, A., Schmaltz, C. A. S., Sant'anna, F. M., Maia, I. R., Hadad, D. J., . . . Rolla, V. (2018, December 25). Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial. BioMed Research International, 1-12.
Cita Chicago Style (17a ed.)
Xavier, Mariana S., Anete Trajman, Carolina A. S. Schmaltz, Flavia M. Sant'anna, Ivan R. Maia, David J. Hadad, Pedro Emmanuel A. A. do Brasil, y Valeria Rolla. "Daily 800 Mg Versus 600 Mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial." BioMed Research International 25 Dec. 2018: 1-12.
Cita MLA (9a ed.)
Xavier, Mariana S., et al. "Daily 800 Mg Versus 600 Mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial." BioMed Research International, 25 Dec. 2018, pp. 1-12.
Precaución: Estas citas no son 100% exactas.